Sarcoidosis versus Granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency: a comparative review
H Buso, C Discardi, P Bez, F Muscianisi… - …, 2024 - pmc.ncbi.nlm.nih.gov
Sarcoidosis and Granulomatous and Lymphocytic Interstitial Lung Diseases (GLILD) are two
rare entities primarily characterised by the development of Interstitial Lung Disease (ILD) in …
rare entities primarily characterised by the development of Interstitial Lung Disease (ILD) in …
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer
M Croft, S Salek-Ardakani, CF Ware - Nature Reviews Drug Discovery, 2024 - nature.com
The first anti-tumour necrosis factor (TNF) monoclonal antibody, infliximab (Remicade),
celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved …
celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved …
[PDF][PDF] Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response
HCB Leffers, B Baslund, J Lindhardsen… - Clinical and …, 2024 - clinexprheumatol.org
Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment
response Page 1 Clinical and Experimental Rheumatology 2022 Clinical and Experimental …
response Page 1 Clinical and Experimental Rheumatology 2022 Clinical and Experimental …
Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis
JG Garweg, KA Straessle - Ocular immunology and inflammation, 2024 - Taylor & Francis
Purpose Janus kinase (JAK) inhibitors have recently been used to treat patients with
biologic refractory noninfectious uveitis (NIU). This narrative review updates the current …
biologic refractory noninfectious uveitis (NIU). This narrative review updates the current …
[HTML][HTML] Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib
G Russo, E Laffitte - Acta Dermato-venereologica, 2024 - ncbi.nlm.nih.gov
DISCUSSION The treatment of cutaneous sarcoidosis is mostly based on clinical experience
and small series. Dermocorticoids are the agents most frequently employed. When skin …
and small series. Dermocorticoids are the agents most frequently employed. When skin …
[HTML][HTML] Recalcitrant cutaneous sarcoidosis treated with upadacitinib: Case report
M Safadi, K Whittington, S Zahner, I Rubinstein… - JAAD Case Reports, 2024 - Elsevier
Sarcoidosis is a multisystem chronic inflammatory disorder that is characterized by
noncaseating granulomas and has an incidence of 1 to 160 per 100,000 persons depending …
noncaseating granulomas and has an incidence of 1 to 160 per 100,000 persons depending …
Salvage use of tofacitinib in sarcoidosis patient with refractory multiorgan involvement
I Farinha, PG Ferreira - Sarcoidosis, Vasculitis, and Diffuse …, 2024 - pmc.ncbi.nlm.nih.gov
A 44-year-old man with severe sarcoidosis with multiorgan involvement was referred to a
tertiary care Interstitial Lung Diseases (ILD) clinic due to clinical and functional respiratory …
tertiary care Interstitial Lung Diseases (ILD) clinic due to clinical and functional respiratory …
Kutane Sarkoidose
F Schauer, R Diehl - Arthritis und Rheuma, 2024 - thieme-connect.com
Die Sarkoidose ist eine Multisystemerkrankung, deren Ursache bislang ungeklärt ist.
Pathognomonisch sind nicht verkäsende Granulome, die alle Gewebe oder Organsysteme …
Pathognomonisch sind nicht verkäsende Granulome, die alle Gewebe oder Organsysteme …
[PDF][PDF] FACULTA DE MEDICINA DIVISIÓN DE ESTUDIOS DE POSGRADO
AA RODRÍGUEZ - 2025 - ru.dgb.unam.mx
Introducción: La sarcoidosis es una enfermedad multisistémica de etiología desconocida,
caracterizada por la acumulación de granulomas no caseificantes en diversos tejidos. El …
caracterizada por la acumulación de granulomas no caseificantes en diversos tejidos. El …